These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3621786)

  • 1. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic fate of phenprocoumon in humans.
    Toon S; Heimark LD; Trager WF; O'Reilly RA
    J Pharm Sci; 1985 Oct; 74(10):1037-40. PubMed ID: 4078699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The warfarin-sulfinpyrazone interaction: stereochemical considerations.
    Toon S; Low LK; Gibaldi M; Trager WF; O'Reilly RA; Motley CH; Goulart DA
    Clin Pharmacol Ther; 1986 Jan; 39(1):15-24. PubMed ID: 3943265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats.
    Schmidt W; Jähnchen E
    J Pharm Pharmacol; 1977 May; 29(5):266-71. PubMed ID: 17688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine.
    de Vries JX; Völker U
    J Chromatogr; 1989 Aug; 493(1):149-56. PubMed ID: 2778004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon.
    O'Reilly RA
    Arch Intern Med; 1982 Sep; 142(9):1634-7. PubMed ID: 7114982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of induction and inhibition of drug metabolism on pharmacokinetics and anticoagulant activity of the enantiomers of phenprocoumon in rats.
    Schmidt W; Trenk D; Jähnchen E
    Pharmacology; 1980; 21(5):313-22. PubMed ID: 7433511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
    Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE
    Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
    Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
    Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of the warfarin-rifampin drug interaction in humans.
    Heimark LD; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Oct; 42(4):388-94. PubMed ID: 3665337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.
    Schmidt W; Jähnchen E
    J Pharmacokinet Biopharm; 1979 Dec; 7(6):643-63. PubMed ID: 529027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers.
    Haustein KO
    Biomed Biochim Acta; 1984; 43(12):1417-24. PubMed ID: 6534380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereochemical aspects of the metabolism of phenprocoumon in rat liver microsomes.
    Wheeler C; Trager WF; Porter WR
    Biochem Pharmacol; 1981 Jul; 30(13):1785-90. PubMed ID: 7271865
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigations into the binding of phenprocoumon to albumin using fluorescence spectroscopy.
    Otagiri M; Fleitman JS; Perrin JH
    J Pharm Pharmacol; 1980 Jul; 32(7):478-82. PubMed ID: 6105183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial models of mammalian metabolism: production of novel alpha-diketone metabolites of warfarin and phenprocoumon using Aspergillus niger.
    Rizzo JD; Davis PJ
    Xenobiotica; 1988 Dec; 18(12):1425-37. PubMed ID: 3245234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.
    Meinertz T; Gilfrich HJ; Groth U; Jonen HG; Jähnchen E
    Clin Pharmacol Ther; 1977 Jun; 21(6):731-5. PubMed ID: 862312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of wheat bran on the pharmacokinetics of phenprocoumon in normal volunteers.
    Kitteringham NR; Mineshita S; Ohnhaus EE
    Klin Wochenschr; 1985 Jun; 63(12):537-9. PubMed ID: 2993733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
    He M; Kunze KL; Trager WF
    Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.
    Jähnchen E; Meinertz T; Gilfrich HJ; Groth U; Martini A
    Clin Pharmacol Ther; 1976 Sep; 20(3):342-9. PubMed ID: 954354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.